Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 5/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.40 |
| ▸ | AHR | P35869 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22803890 | 1.00 | SYK (0.49) | SYKRETMEN1POLBMAPK1 | |
| SCHEMBL22803936 | 0.90 | SYK (0.46) | SYKPRKCQAHREGFRMAOA | |
| SCHEMBL22803666 | 0.83 | SYK (0.52) | SYKRETESR1APPAHR | |
| SCHEMBL22803920 | 0.82 | RET (0.52) | SYKRETMEN1POLBMAPK1 | |
| SCHEMBL30302517 | 0.82 | RET (0.52) | SYKRETMEN1POLBMAPK1 | |
| SCHEMBL22803924 | 0.81 | PRKCQ (0.52) | SYKRETMEN1POLBMAPK1 | |
| SCHEMBL22803619 | 0.81 | RET (0.44) | SYKRETMEN1POLBMAPK1 | |
| SCHEMBL22803923 | 0.81 | RET (0.43) | SYKRETMEN1POLBMAPK1 | |
| SCHEMBL22803925 | 0.78 | RET (0.53) | SYKRETMEN1POLBMAPK1 | |
| SCHEMBL22803640 | 0.77 | MEN1 (0.57) | SYKRETMEN1POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092163-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | SYK 748/4885RET 1978/4885MEN1 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.